生物制品行业深度报告：MNC加速布局减重降糖千亿美金赛道，开启BD黄金窗口期

开源证券2025-06-20

（以下内容从开源证券《生物制品行业深度报告：MNC加速布局减重降糖千亿美金赛道，开启BD黄金窗口期》研报附件原文摘录）MNC加速布局减重降糖千亿美金赛道，开启BD黄金窗口期以司美格鲁肽与替尔泊肽为代表的GLP-1RA类药物正在彻底改变糖尿病与肥胖症的治疗范式，根据Jefferies等数据统计，2031年预计GLP-1RA类药物全球销售规模有望超过1500亿美元规模。诺和诺德与礼来两大MNC旗下产品...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2544192772?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-06-20 08:06","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2544192772","market":"sh","top_or_hot":-1,"title":"生物制品行业深度报告：MNC加速布局减重降糖千亿美金赛道，开启BD黄金窗口期","media":"开源证券","content":"<div>\n<p>（以下内容从开源证券《生物制品行业深度报告：MNC加速布局减重降糖千亿美金赛道，开启BD黄金窗口期》研报附件原文摘录）MNC加速布局减重降糖千亿美金赛道，开启BD黄金窗口期以司美格鲁肽与替尔泊肽为代表的GLP-1RA类药物正在彻底改变糖尿病与肥胖症的治疗范式，根据Jefferies等数据统计，2031年预计GLP-1RA类药物全球销售规模有望超过1500亿美元规模。诺和诺德与礼来两大MNC旗下产品...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202506200806389523e82d&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>生物制品行业深度报告：MNC加速布局减重降糖千亿美金赛道，开启BD黄金窗口期</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n生物制品行业深度报告：MNC加速布局减重降糖千亿美金赛道，开启BD黄金窗口期\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-06-20 08:06 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202506200806389523e82d&s=b><strong>开源证券</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>（以下内容从开源证券《生物制品行业深度报告：MNC加速布局减重降糖千亿美金赛道，开启BD黄金窗口期》研报附件原文摘录）MNC加速布局减重降糖千亿美金赛道，开启BD黄金窗口期以司美格鲁肽与替尔泊肽为代表的GLP-1RA类药物正在彻底改变糖尿病与肥胖症的治疗范式，根据Jefferies等数据统计，2031年预计GLP-1RA类药物全球销售规模有望超过1500亿美元规模。诺和诺德与礼来两大MNC旗下产品...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202506200806389523e82d&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"159831","symbol_name":"黄金","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202506200806389523e82d&s=b","article_id":"2544192772","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202506200806389523e82d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2544192772","pubTimestamp":1750377989,"columns":[{"name":"黄金","id":5,"label_key":null}],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"MNC加速布局减重降糖千亿美金赛道，开启BD黄金窗口期以司美格鲁肽与替尔泊肽为代表的GLP-1RA类药物正在彻底改变糖尿病与肥胖症的治疗范式，根据Jefferies等数据统计，2031年预计GLP-1RA类药物全球销售规模有望超过1500亿美元规模。近年来减重降糖领域重磅BD交易频发，我们预期将迎来BD黄金窗口期，国内企业相关管线将迎来历史性出海机遇。随着海外MNC加速布局该赛道，国内优质管线均有较强出海潜力，有望打开成长空间。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"159831":"黄金","600161":"天坛生物","600211":"西藏药业","600739":"辽宁成大","600867":"通化东宝","603087":"甘李药业","603392":"万泰生物","603590":"康辰药业","688105":"诺唯赞","688136":"科兴制药","688137":"近岸蛋白","688163":"赛伦生物","688177":"百奥泰","688180":"君实生物","688185":"康希诺","688276":"百克生物","688278":"特宝生物","688293":"奥浦迈","688319":"欧林生物","688331":"荣昌生物","688336":"三生国健","688443":"智翔金泰","688488":"艾迪药业","688520":"神州细胞","688670":"金迪克","688687":"凯因科技","688739":"成大生物","BK0033":"西藏振兴","BK0239":"医药制造"},"translate_title":"In-depth report on the biological products industry: MNC accelerates the layout of the 100-billion-dollar track of weight loss and blood sugar reduction, opening the golden window period of BD","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159831":1,"600161":0.9,"600211":0.9,"600739":0.9,"600867":0.9,"603087":0.9,"603392":0.9,"603590":0.9,"688105":0.9,"688136":0.9,"688137":0.9,"688163":0.9,"688177":0.9,"688180":0.9,"688185":0.9,"688276":0.9,"688278":0.9,"688293":0.9,"688319":0.9,"688331":0.9,"688336":0.9,"688443":0.9,"688488":0.9,"688520":0.9,"688670":0.9,"688687":0.9,"688739":0.9},"content_text":"（以下内容从开源证券《生物制品行业深度报告：MNC加速布局减重降糖千亿美金赛道，开启BD黄金窗口期》研报附件原文摘录）MNC加速布局减重降糖千亿美金赛道，开启BD黄金窗口期以司美格鲁肽与替尔泊肽为代表的GLP-1RA类药物正在彻底改变糖尿病与肥胖症的治疗范式，根据Jefferies等数据统计，2031年预计GLP-1RA类药物全球销售规模有望超过1500亿美元规模。诺和诺德与礼来两大MNC旗下产品目前患者市占率已接近97%，形成双巨头垄断市场格局；默沙东、罗氏、安进、阿斯利康与再生元等正快速进入该赛道中，在一个或多个细分方向上布局潜力品种；其余MNC目前尚未完整布局该领域，未来有较大License-in的可能性。近年来减重降糖领域重磅BD交易频发，我们预期将迎来BD黄金窗口期，国内企业相关管线将迎来历史性出海机遇。患者依从性提升：口服与超长效产品有望提供新的解决方案为提高患者依从性，目前主要从口服GLP-1RA类药物与超长效药物两类技术路径进行布局。目前在研阶段的口服管线主要包括小分子类与多肽类，其中化药类进度较快的有礼来的Orforglipron，多家其他MNC也均有在研管线；多肽类口服药主要由诺和诺德布局。作为长效制剂，司美格鲁肽与替尔泊肽已实现每周给药，相较于每日给药的利拉鲁肽，给药间隔已大幅延长。超长效制剂的体内半衰期相对更长，能够实现每2周给药甚至每4周给药，减少患者的用药频率，简化治疗流程的同时提升患者依从性。目前在研阶段进度较快的超长效减肥药有安进的MariTide（Q4W），Metsera的MET-097i（Q4W）与MET-233i（Q4W）。高质量减重：多靶药物开发与特殊靶点组合疗法有望突破单一靶点瓶颈相较于单一GLP-1R靶点，多靶点减肥药物通过协同激活或抑制多个代谢相关受体，能够突破单一靶点的疗效瓶颈，实现“抑制食欲+加速代谢+器官保护”的协同机制，在减重效果、代谢综合改善和用药依从性上实现显著提升。热门布局靶点包括GIPR、GCGR与AMYR等。除此之外，与一些特殊靶点的协同联用也有望成为高质量减重下一阶段的发展方向。热门布局靶点包括ActRII、MSTN/GDF-8、AMYR、FGF21等。通过与其协同联用，在增强减重效果的同时也有望改善代谢、保留瘦体重；“减脂增肌+代谢修复”有望成为未来减重领域的新标准。投资建议患者依从性的提升与高质量减重将成为下一代减重降糖药物开发新方向，中国企业在口服、超长效、多靶、组合疗法等新一代热门靶点与技术领域均有管线布局，数量与质量均做到了全球领先。随着海外MNC加速布局该赛道，国内优质管线均有较强出海潜力，有望打开成长空间。推荐标的：信达生物、华东医药、博瑞医药、一品红、康缘药业等；受益标的：恒瑞医药、石药集团、翰森制药、众生药业、歌礼制药-B、来凯医药-B等。风险提示：创新药研发热度下滑、药物临床研发失败、药物安全性风险等。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2544192772","isCrawlerRequest":true}